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doi:10.101Selecting Donor RecipientsYou are selecting an unrelated donor for a 40-year-old man with acute myelogenous leukemia (AML) in second
complete remission (CR2) with high-risk cytogenetics. He is cytomegalovirus (CMV) seronegative with blood type
A2. He is an only child. The search coordinators have identified the following options:
Donor Age sex HLA matching 9/10 matched donors CMV status Blood type
1 50 F Single allele mismatch at HLA-A CMV2 A1
2 30 M Single allele mismatch at HLA-C CMV1 O1
3 30 M Single antigen mismatch at HLA-DQ CMV1 A1/09/1503-0001$
6/j.bbmt.2008.0536.00/0
.013Which donor would you select?
 Donor 1
 Donor 2
 Donor 3
Biol Blood Marrow Transplant 15:393-394 (2009)  2009 American Society for Blood and Marrow TransplantationREADER RESPONSES
In a recent issue of the ASBMT eNEWS, readers
were presented with the above question and invited
to use an online poll to respond. The reader responses
were:
 24% First donor option
 22% Second donor option
 54% Third donor optionCOMMENTARY
Despite more than 11 million typed volunteers
in hematopoietic donor registries worldwide (www.
bmdw.org), many patients do not find a fully HLA
matched donor. The questions therefore become
which donor is the closest match, how much would
the detected disparity impact patient outcomes, and
would a transplant from the best partially matched
donor still be preferable compared to nontransplant
therapies.
In this month’s case, respondents favored a donor
mismatched for 1 HLA-DQ ‘‘antigen’’ (ie,
DQB1*0101 versus 0301) to donors mismatched at 1
HLA-A ‘‘allele’’ (ie, A*0101 versus *0102) or 1 C
‘‘allele’’ (ie, C*0701 versus *0702), and the top choice
coincides with my preference as well. Reports ofunrelated donor marrow transplantation from the
United States and the Japan Marrow Donor Program
including more than 5000 patients failed to detect
a significant association of an isolated HLA-DQB1
mismatch with any patient outcomes [1,2]. Thus, this
donor would provide similar survival to a fully
HLA-A, -B, -C, -DRB1, or -DQB1matched unrelated
donor.
Mismatching for HLA-A was associated with in-
creased mortality in both the United States and Japa-
nese registry studies, whereas 1 isolated mismatch for
HLA-B or -C was less significant in the U.S. study
[1], and HLA-C was not significant in the Japanese
study [2]; thus, I would have ranked donor 2 better
than donor 1. The fact that the mismatch at HLA-A
is for an allele and not an antigen does not mitigate
the risk, as in the U.S. analysis, an A allele mismatch
was associated with a mortality relative risk of 1.5
(95% confidence interval [CI] 1.2-1.9) [1]. Because
donor 2 is mismatched for 1 HLA-C allele, and the
relative risk of death for such a mismatch was 1.0
(95% CI 0.8-1.3), I would have expected this donor
to have garnered as many votes as donor 3, who was
mismatched at HLA-DQ [1]. Obviously not all
disparities are equally functional, but there are only
early reports about potential criteria for identifying
permissible mismatches by polymorphisms away from
the sites of peptide anchor residues [3]. TheKIR-bind-
ingHLA-C allotypes are usually identical within allelic
disparities, but if the mismatch were for an HLA-C393
394 C. Anasettiantigen and for a KIR-ligand allotype, consideration
shouldhavebeengiven to enrolling thepatient on a trial
to test the potential benefits of donor natural killer
(NK) allo-reactivity with a T cell-depleted graft, based
on data from mismatched related transplants [4].
The literature does not provide definitive evidence
from prospective-controlled studies that a closely
matched unrelated donor transplant improves survival
of a patient with acute myelogenous leukemia (AML)
in second remission (CR2) when compared to an au-
tologous transplant or nontransplant therapies, but
a case series and consensus guidelines of an expert
panel support this recommendation, especially with
high-risk cytogenetics, based on retrospective studies
[5,6]. I will not address the issue of selecting cord
blood units or a related donor mismatched for a whole
HLA haplotype, because a suitably matched unrelated
donor is already in hand.
Donor age is often ignored in the selection process,
but data from large transplant data sets found a signif-
icant albeit small (3% per decade of age) association
of younger donor age with less mortality [7], another
factor that did not weigh negatively in the selection
of donor 1 as much as I would have expected.
We often try to select a cytomegalovirus (CMV)-
seronegative donor for a seronegative patient, and
this might be one reason why donor 1 scored relatively
high in the poll, but such a donor does not improve
survival compared to a CMV-seropositive donor [7].
We are similarly concerned about selecting female do-
nors for male patients, because it increases the inci-
dence of acute and chronic graft-versus-host disease
(aGVHD, cGVHD), the duration of cGVHD, and
the nonrelapse mortality, but the use of a female donor
is also associated with less posttransplant relapse, and
therefore survival of male patients with malignancy is
in general not affected by the donor gender [7]. Appar-
ently, these morbidity concerns did not influence
respondents’ votes because donor 1, a female, was
given as much preference as donor 2, a male. Delayed
red cell recovery occurs after donormajor ABO dispar-
ity but has not been reported with Rhmajor disparities.
Delayed transfusion reactions with intravascular he-
molysis can occur with transplants from donor type
O into recipient A or B, but these are rare and occur
almost exclusively in patients treated with a calcineurin
inhibitor alone. Therefore, donor ABO would not be
a helpful criterion for donor selection in this case, if
the planned GVHD prophylaxis is a drug combina-
tion.Should we choose mobilized blood or marrow
stem cells from donor 3? The literature has provided
relatively good guidance with an individual patient
meta-analysis of 9 randomized trials in sibling trans-
plantation, but retrospective series show little differ-
ence in relapse and survival between patients treated
with 1 of the 2 sources from an unrelated donor [8].
The increased risk of aGVHD and cGVHD should
deter the use of mobilized blood, but the high risk of
relapse in a patient with AML with high-risk cytoge-
netics in second remission should favor mobilized
blood. To help answer this question, patients should
be enrolled on the ongoing BMT-CTN 0201 trial
that randomizes 1:1 between the 2 sources (https://
web.emmes.com/study/bmt).
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